Table 1b. Table 1b: Oncogenes in HGSOC.
| GENE | CHR | FREQUENCY OF ALTERATION | FUNCTIONS | OUTCOME | REF | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| REPORT(N) | TCGA (N = 316) | IN VITRO | IN VIVO | REPORT | TCGA | |||||
| AMP | OV EXP (RNA/PTN) | AMP | OV EXP (RNA) | |||||||
| FOXP1 | 3q13 | NA | NA | 1.9% | 1.6% | Cancer stem cell properties ,spheroid formation, EMT, migration & chemoresistance | Knockdown reduced tumor growth | NA | NS | [96] |
| FGFRL1 | 4p16.3 | NA | NA | 1.9% | 3.16% | Cell proliferation & migration | Knockdown reduced tumor growth | ↓ OS | NS | [97] |
| PITX2 | 4q25 | NA | NA | - | 2.5% | Cell proliferation, anchorage independent growth & invasion | Ectopic expression induced tumors | NA | NS | [98] |
| OCT4A | 6p21.33 | NA | NA | 2.5% | 2.8% | Cell survival, metastasis & chemoresistance | Knockdown reduced tumor growth & metastasis | NA | NS | [99] |
| CTHRC1 | 8q22.3 | NA | NA | 8.8% | 2.8% | EMT | Knockdown prevented the metastasis of tumors | ↓ PFS & OS | NS | [100] |
| FOXM1 | 12p13.33 | NA | NA | 6% | 4.1% | Cell proliferation, migration & invasion | Knockdown reduced the tumor growth,ascites& number of tumor nodules | NA | NS | [101] |
| ITGA5 | 12q13.13 | NA | 39% (107) | 1.2% | 5% | Cell adhesiion & invasion | Knockdown resulted in a decrease in the number of intra abdominal mets, reduced ascites formation, smaller tumor nodules & increased survival | ↓PFS & OS | NS | [102] |
| STAT3 | 17q21.2 | NA | NA | NA | 0.9% | Migration& Invasion | Knockdown reduced tumor growth | NA | NS | [103] |
| DGCR8 | 22q11.21 | NA | NA | 0.9% | 3.4% | Proliferation, migration & invasion | Knockdown reduced tumor growth | NA | NS | [104] |
The above mentioned genes are altered in <10% of patients with HGSOC
Abbreviations: N, No. of Samples; CNA, Copy number array; EXP, Overexpression of the gene at RNA level; PTN, Protein; OS, overall survival; PFS, Progression free survival; NA, Not available; NS, Not significant.
Only three genes mentioned in the tables above were identified using different techniques; RAB25 (Comparative Genomic Hydribization), RPL22L1 (Degenerate oligonucleotide-primed polymerase chain reaction), and FABP4 (in silico analysis). Other genes are reported from publications.
The genes in italic font are druggable targets based on the data from IDG (Illuminating the Druggable Genome) database (https://commonfund.nih.gov/idg/index).
The information for a specific gene and its impact on survival of the patients with HGSOC (n=316) was determined using TCGA HGSOC data set (n=316) on cBioPortal
(https://www.cBioPortal.org/) The thresholds used in the analysis were: GENE NAME: AMP & EXP >=2